FrenzelTLengsfeldPSchirmeret al.Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 37℃. Invest Radiol2008; 43: 817–828.
2.
FretellierNSalhiMSchroederJet al.Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: Role of pharmaceutical formulation. Eur J Pharm Sciences2015; 72: 46–56.
3.
HaylorJSchroederJWagnerBet al.Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology2012; 263: 107–116.
4.
IdéeJ-MFretellierNRobicCet al.The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Crit Rev Toxicol2014; 44: 895–913.
5.
PietschHJostGFrenzelTet al.Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol2011; 80: 349–356.
6.
ShellockFGSpinazziA. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. Am J Roentgenol2008; 191: 1129–1139.
7.
SieberMALengsfeldPWalterJet al.Gadolinium based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging2008; 27: 955–962.
8.
SoulezGBloomgardenDCRofskyNet al.Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3–5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. Am J Roentgenol2015; 205: 469–478.
9.
WhiteGWGibbyTweedleMF. Comparison of Gd (DTPA-BMA) (Omniscan) versus GD (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol2006; 41: 272–278.
